Daily Trades
- Dylan Jovine
- Saturday, November 18, 2023
When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
- Dylan Jovine
- Monday, August 7, 2023
Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
- Dylan Jovine
- Thursday, March 16, 2023
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
- Tuesday, January 18, 2022
- Dylan Jovine
- Friday, September 18, 2020
- Dylan Jovine
- Saturday, November 18, 2023
When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
- Dylan Jovine
- Monday, August 7, 2023
Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
- Dylan Jovine
- Thursday, March 16, 2023
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
- Tuesday, January 18, 2022
- Dylan Jovine
- Friday, September 18, 2020
deal of the month
Categories
Dylan Jovine - "Uncovering the Game-Changing Drug of the Decade"
Protecting Your Financial Security from China's Attack on the US Dollar
Fed Rates Impacting Bonds: Explaining Maturity Length
Recent posts
Tags
Connect with Us
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
